Feasibility Study Extended by 12 Months
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Polynovo
- PolyNovo US Patent Allowed
- PolyNovo US Collaboration Update
- Polynovo to Commence First Human Trial
- PolyNovo Human Trial Update
- Polynovo Completes Pivotal Study on Burns
Later from Polynovo
- US Regulatory Update
- Additional BARDA Option Exercised Valued at US$2.4m
- BTM use in Diabetes Islet Cell Transplantation Study
- Financial result guidance
- Full Year Statutory Accounts and Appendix 4E
Follow Polynovo into a list and get an email when it puts out news.
Follow Polynovo